Asterias Biotherapeutics' SCiStar Phase 1/2a clinical study yielded positive outcomes for patients with complete cervical spinal cord injury.
Here are four notes:
1. The nine-month study tested the efficacy and safety study of AST-OPC1, a human stem cell-based treatment for SCI patients.
2. Researchers saw three out of six patients, treated with 10 million cells, achieved two motor levels of improvement over baseline on at least one side following treatment.
3. All six patients experienced at least one motor level of improvement on at least one side.
4. Researchers presented the data at a pre-meeting workshop at the International Society for Stem Cell Research 2017 Annual Meeting in Boston from June 14 to June 17.